文献速递心外重症与机械循环支持

双心室支持:体内植入连续流离心泵的预后与不良事件

Biventricular Support With Intracorporeal, Continuous Flow, Centrifugal Ventricular Assist Devices.
PubMed 文献 · Ann Thorac Surg · 2017-11-20

研究纳入38例INTERMACS注册的成人患者,在2012年11月至2015年6月间接受两台耐久性体内连续流离心泵行双心室支持。6个月生存率68%、12个月62%,感染50%、出血44%等不良事件常见,提示该配置死亡与并发症负担高,需进一步研究。

要点

  • 双心室连续流离心泵支持6个月生存率68%、12个月62%。
  • 常见不良事件:感染50%、出血44%、呼吸衰竭31.6%。
  • 装置 malfunction 26.3%、神经功能障碍26.3%、肾功能障碍18.4%。

核心结论

  • 耐久性体内连续流离心泵用于晚期双心室心衰与高发病率和高死亡率相关。
  • 该作者认为有必要进一步研究这种装置配置。

研究设计与样本

  • 回顾性多中心队列,38例来自INTERMACS的成人患者,2012年11月至2015年6月接受两台耐久性体内连续流离心泵双心室支持。
  • 排除儿童患者,平均年龄47岁,74%为男性。

主要发现

  • 原发病为特发性扩张型心肌病37%、缺血性16%。
  • 6个月生存率68%,12个月生存率62%。
  • 左心室辅助装置置于左心室心尖91%,位置未注明9%。
  • 右心室辅助装置置于右心室50%、右心房37%、未注明13%。

关键数值与推荐

  • 不良事件:感染50%、出血44%、呼吸衰竭31.6%、装置故障26.3%、神经功能障碍26.3%、肾功能障碍18.4%、心律失常18.4%。

临床怎么用

  • 对晚期双心室心衰考虑耐久性体内连续流离心泵双心室支持时,应充分告知高死亡与高并发症风险。
  • 需多中心进一步研究该装置配置以优化患者选择与管理。

局限性

  • 原文未报告局限性内容。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The incidence of right ventricular dysfunction requiring right ventricular assist device after left ventricular assist device placement has been reported between 10% to 30%. The mortality rate is higher compared with patients who require left ventricular assist device only; the most effective and safest biventricular assist device remains unknown. We aimed to determine the survival outcomes and frequency of adverse events in patients with two durable, intracorporeal, continuous flow centrifugal pumps for support. METHODS: Between November 2012 and June 2015, 38 patients were identified from INTERMACS received durable, intracorporeal continuous flow centrifugal pumps for biventricular support. Pediatric patients were excluded. Mean age was 47 years, and 74% of patients were male. The common primary diagnoses in this cohort were dilated myopathy, idiopathic (37%) and ischemic (16%). RESULTS: Nineteen participating centers implanted devices in 38 patients; 11 patients died with device in place, 9 patients received a heart transplant, and 18 were alive on support with the right ventricular assist device in place. Survival outcomes were 68% at 6 months and 62% at 12 months. The left ventricular assist device was placed in the left ventricle apex in 91% of cases, and in 9%, the location was not specified. The right ventricular assist device was placed in the right ventricle in 50%, right atrium in 37%, and not specified in 13%. The adverse events included infection 50%, bleeding 44%, respiratory failure 31.6%, and malfunction 26.3%; neurologic dysfunction 26.3%; renal dysfunction 18.4%; and arrhythmia 18.4%. CONCLUSIONS: The use of durable, intracorporeal, continuous flow centrifugal pumps for management of advanced biventricular heart failure is associated with high morbidity and mortality. Further investigation of this device configuration is warranted.

来源:Ann Thorac Surg,查看原文。版权归原作者所有。

引用

  1. Arabía FA, Milano CA, Mahr C, et al. Biventricular Support With Intracorporeal, Continuous Flow, Centrifugal Ventricular Assist Devices. Ann Thorac Surg. 2017. PMID: 29157741. doi:10.1016/j.athoracsur.2017.08.019

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。